The Canada-based biopharmaceutical company MedC Biopharma has partnered with Maltese production facility A2W Pharm to develop new cannabis-based treatments for cancer-related conditions.
The partnership will centre around the development of MedC’s proprietary novel cannabinoid formulations for the treatment of various cancer-related indications. As part of the agreement, A2W has committed to investing around 2 million euros directly into the drug development of MedC’s patented cutaneous T-cell lymphoma (CTCL) treatments.
MedC Biopharma is focused on cannabinoid drug therapeutics. The company’s methodology rapidly screens for combinations of synergetic cannabinoids in treating various medical indications, with skin cancers being the firm’s primary targets. MedC has so far discovered and developed two patented cannabinoid combinations for the treatment of CTCL Sezary, CTCL Mycosis Fungoides and Actinic Keratosis.
“We are very excited about collaborating with A2W on our drug development program,” said Avi Drori, CEO of MedC. “A2W’s strategy fits perfectly with ours, bridging the gap between cannabinoid-based medication and regulatory requirement through synthesised therapeutics which guarantees safety, consistency and predictability that both patient and doctors justly expect.”
A2W Pharma, a subsidiary of Amino Chemicals of Malta, launched a new cannabinoid production facility in Malta in 2022 and is focused on bridging the gaps that exist between pharmacology and medicine. The company says it aims to give patients better access to the benefits that lie within the cannabis plant.
Peter Paul Farrugia, director of A2W said: “A2W leverages 30 years’ experience of its parent company Amino Chemicals in API process development, GMP and regulatory compliance, and innovative routes to target cannabinoid molecules mean we are the partner of choice for a successful launch of your pharmaceutical formulation.
“The cooperation between both organisations will expedite MedC’s clinical and commercial programs, overcoming regulatory challenges and bringing hope for skin cancer patients worldwide.”
MedC Biopharma is a clinical-stage biopharmaceutical company focused on the development of cancer-related cannabinoid-based therapeutic formulations and medicines. Its research and development is carried out by Professor Hinanit Koltai who has developed a state of the art drug discovery platform.
